Related Experiment Video
Updated: Jan 21, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
Mark N Stein1,2,3, Susan Goodin4,5, Murugeson Gounder4,5
1Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ, 08903, USA. mns2146@cumc.columbia.edu.
Abstract:
Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Methods Patients were treated with AT-101 (40 mg) every 12 h on days 1, 2 and 3 of each cycle combined with varying dose levels (DL) of paclitaxel and carboplatin [DL1: paclitaxel (150 mg/m2) and carboplatin (AUC 5) on day 1 of each cycle; DL2: paclitaxel (175 mg/m2) and carboplatin (AUC 6) on day 1 of each cycle]. Secondary objectives included characterizing toxicity, efficacy, pharmacokinetics, and pharmacodynamics of the combination. Results Twenty-four patients were treated across two DLs with a planned expansion cohort. The most common tumor type was prostate (N = 11). Two patients experienced DLTs: grade 3 abdominal pain at DL1 and grade 3 ALT increase at DL2; however, the MTD was not determined. Moderate hematologic toxicity was observed. One CR was seen in a patient with esophageal cancer and 4 patients achieved PRs (1 NSCLC, 3 prostate). PD studies did not yield statistically significant decreases in Bcl-2 and caspase 3 protein levels, or increased apoptotic activity induced by AT-101. Conclusion The combination of AT-101 at 40 mg every 12 h on days 1, 2 and 3 combined with paclitaxel and carboplatin was safe and tolerable. Based on the modest clinical efficacy seen in this trial, this combination will not be further investigated. Clinical Trial Registration: NCT00891072, CTEP#: 8016.
Insights
The combination of AT-101 with paclitaxel and carboplatin showed moderate toxicity in advanced solid tumors. Clinical efficacy was modest, and this combination will not be further investigated.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- AT-101 is a BH3 mimetic targeting anti-apoptotic proteins like Bcl-2.
- It aims to lower the threshold for apoptosis by inhibiting protein heterodimerization.
- This study explores its use in advanced solid tumors.
Purpose of the Study:
- Investigate the maximum tolerated dose (MTD) of AT-101 combined with paclitaxel and carboplatin.
- Characterize the toxicity, efficacy, pharmacokinetics, and pharmacodynamics of this combination therapy.
- Evaluate the potential of this combination in treating advanced solid tumors.
Main Methods:
- A phase I clinical trial was conducted with patients receiving AT-101 (40 mg q12h on days 1-3) plus escalating doses of paclitaxel and carboplatin.
- Two dose levels (DL1 and DL2) were evaluated, with dose-limiting toxicities (DLTs) monitored.
- Secondary objectives included pharmacokinetic and pharmacodynamic assessments.
Main Results:
- Twenty-four patients were enrolled; prostate cancer was the most common diagnosis (N=11).
- Two DLTs were observed (grade 3 abdominal pain, grade 3 ALT increase), but the MTD was not determined.
- One complete response (esophageal cancer) and four partial responses (1 NSCLC, 3 prostate) were recorded; pharmacodynamic studies showed no significant changes in target proteins or apoptosis.
Conclusions:
- The combination of AT-101, paclitaxel, and carboplatin was found to be safe and tolerable in patients with advanced solid tumors.
- Due to modest clinical efficacy observed in this phase I trial, further investigation of this specific combination is not planned.
- The study provides safety and preliminary efficacy data for this novel combination therapy.
Related Concept Videos
Phase Diagrams
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Phase Transitions
Phase Transitions: Sublimation and Deposition
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...

![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)